



SSmooth muscle phenotypic modulation is an early event in aortic
aneurysms
Gorav Ailawadi, MD,a Christopher W. Moehle, BS,b Hong Pei, MD,a Sandra P. Walton, BS,a
Zequan Yang, MD, PhD,a Irving L. Kron, MD,a Christine L. Lau, MD,a and Gary K. Owens, PhDb
Objectives: Vascular smooth muscle cells can undergo profound changes in phenotype, defined by coordi-
nated repression of smooth muscle cell marker genes and production of matrix metalloproteinases in re-
sponse to injury. However, little is known of the role of smooth muscle cells in aortic aneurysms. We
hypothesized that smooth muscle cells undergo phenotypic modulation early in the development of aortic
aneurysms.
Methods: Abdominal aortas from C57B6 mice (n ¼ 79) were perfused with elastase or saline (control) and har-
vested at 1, 3, 7, or 14 days. Aortas were analyzed by means of quantitative polymerase chain reaction and im-
munohistochemistry for smooth muscle cell marker genes, including SM22A, smooth muscle a-actin, and matrix
metalloproteinases 2 and 9. In complimentary experiments human aneurysms (n¼ 10) and control aorta (n¼ 10)
were harvested at the time of surgical intervention and analyzed.
Results:By 14 days, aortic diameter was larger after elastase perfusion compared with control diameter (100%
9.6% vs 59.5%  18.9%, P ¼ .0002). At 7 days, elastase-perfused mice had a 78% and 85% reduction in
SM22a and smooth muscle a-actin expression, respectively, compared with that seen in control animals well be-
fore aneurysms were present, and these values remained repressed at 14 days. Immunohistochemistry confirmed
less SM22a and smooth muscle a-actin in experimental aneurysms at 14 days in concert with increased matrix
metalloproteinase 2 and 9 expression at 7 and 14 days. Similarly, human aneurysms had less SM22a and smooth
muscle a-actin and increased matrix metalloproteinase 2 and 9 staining, compared with control values, as deter-
mined by means of quantitative polymerase chain reaction.
Conclusions:Aneurysms demonstrate smooth muscle cell phenotypic modulation characterized by downregu-
lation of smooth muscle cell marker genes and upregulation of matrix metalloproteinases. These events in
experimental models occur before aneurysm formation. Targeting smooth muscle cells to a reparative pheno-
type might provide a novel therapy in the treatment of aortic aneurysms. (J Thorac Cardiovasc Surg
2009;138:1392-9)
EVOLVING TECHNOLOGY/BASIC SCIENCEThe mechanisms involved in aortic aneurysm formation are
not well understood. An unknown inciting event results in
aortic wall injury, whereby leukocytes are recruited into
the aortic wall.1 In response to local inflammatory cytokine
production, macrophages and smooth muscle cells (SMCs)
release proteases, including matrix metalloproteinases
(MMPs), leading to destruction of the extracellular matrix
proteins collagen and elastin.1 Late in the course of aneu-
rysms, SMCs undergo apoptosis, thereby losing the cells pri-
marily responsible for the synthesis of extracellular matrix
proteins. The ongoing shift toward degradation of collagen
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gression of aneurysms.1
It is well established that vascular SMCs have the ability
to undergo profound changes in phenotype in response to
changes in their extracellular environment, as occurs after
vascular injury and in atherosclerosis in both preclinical
animal models and human subjects.2 These changes often
include enhanced proliferation and migration, as well as
marked changes in gene expression patterns, including co-
ordinated repression of SMC marker genes and induction
of MMPs in response to inflammatory mediators.2,3 Specif-
ically, repression of SM22a, smooth muscle (SM) a-actin,
and smooth muscle myosin heavy chain in concert with in-
creased MMP-2, MMP-3, and MMP-9 expression is seen
in patients with atherosclerosis.2 These and other alter-
ations in SMC phenotype are thought to play a key role
in the pathophysiology of multiple disorders, including
atherosclerosis, restenosis, tumor metastasis, and hyperten-
sion.2,3 The focus of much of the work related to the devel-
opment of aortic aneurysms has been on the role of
macrophages and leukocytes, whereas little is known of
the role of SMCs.urgery c December 2009





CABG ¼ coronary artery bypass grafting
KLF ¼ Kru¨ppel-like factor
MMP ¼ matrix metalloproteinase
qPCR ¼ quantitative polymerase chain reaction
SM ¼ smooth muscle
SMC ¼ smooth muscle cell
TGF ¼ transforming growth factor
We hypothesized that SMCs undergo phenotypic switching
early during aneurysm formation and contribute to the de-
struction of aortic wall matrix in response to local inflamma-
tory mediators. Our overall hypothesis is that SMCs, by
altering the phenotype to a differentiated or reparative state,
might be a target to treat aortic aneurysms.
MATERIALS AND METHODS
Murine Aneurysm Model
The elastase perfusion model to create abdominal aortic aneurysms in
mice has been well described.4-6 In this well-accepted model aortas dilate
by 30% to 50% initially after perfusion with elastase or saline. Elastase
perfusion results in progressive aortic dilation such that an aneurysm of
100% over baseline develops by 14 days (Figure 1, B).4-6 In contrast,
saline-perfused aortas do not dilate following perfusion. Briefly, the infrare-
nal abdominal aorta is isolated in situ. Branches are ligated with 7–0 mono-
filament sutures. After occluding the aorta proximally and distally, an
arteriotomy is made at the aortic bifurcation with a 31-gauge needle. The
aorta is cannulated and perfused with porcine pancreatic elastase (0.47 U/
mL) for 5 minutes at a pressure of 100 mm Hg (Figure 1, A). Control ani-
mals are perfused with normal saline (0.9%) for 5 minutes. The arteriotomy
is repaired with interrupted 10–0 monofilament sutures, and flow is re-
established in the aorta. The abdominal contents are replaced, the
abdominal wall is closed, and the mice are recovered. Video micrometric
measurements of the aortic wall diameter are made in situ before perfusion,
after perfusion, and at harvest. All animal protocols described were
approved by the University of Virginia Animal Care and Use Committee
(protocol no. 3634).
The aortas from wild-type C57B6 mice (n ¼ 79) were perfused with
elastase or saline (control). Saline-treated aortas were harvested at 1
(n ¼ 9), 3 (n ¼ 9), 7 (n ¼ 8), or 14 (n¼10) days. Similarly, elastase-treated
aortas were harvested at 1 (n ¼ 9), 3 (n ¼ 10), 7 (n ¼ 12), or 14 (n ¼ 12)
days. Aortas were analyzed by means of real-time quantitative polymerase
chain reaction (qPCR) or immunohistochemistry.
qPCR
Aortas were harvested, flash-frozen in liquid nitrogen, and held at80C
until extraction. RNA was extracted with Trizol (Invitrogen, Carlsbad,
Calif). Briefly, for mice, RNA was extracted from frozen tissue by
pulverizing in Trizol with the Pellet Pestle handheld homogenizer (Thermo
Fisher Scientific, Waltham, Mass). Human tissue was crushed under liquid
nitrogen with a mortar and pestle and further homogenized in Trizol by
using a bead mill (Fast Prep 24; MP Biomedicals, Solon, Ohio). cDNA
was synthesized from extracted RNA with the QuantiTect Reverse
Transcription Kit (Qiagen, Inc, Valencia, Calif). qPCR was performed
with TaqMan Gene Expression probe sets in conjunction with TaqMan
Gene Expression Master Mix (Applied Biosystems, Inc, Foster City, Calif).
Primers and probes used were as follows: 18s (both mouse and
human) forward, CGGCTACCACATCCAAGGAA; 18s reverse, AGThe Journal of Thoracic and CCTGGAATTACCGCGGC; FAM-labeled probe, TGCTGGCACCA
GACTTGCCCTC. Probe sets were for murine SM22A (reference no.
Mm00441660-m1), murine SM a-actin (reference no. Mm01546133-m1),
and murine MMP-2 (reference no. Mm00439506-m1). Human SM a-actin
(reference no. Hs00909449_m1) and human MMP-2 (reference no.
Hs00234422_m1) were purchased from Applied Biosystems. Gene
expression was calculated by using the relative quantification method ac-
cording to the following equation: 2(DCT), where DCT ¼ (Average gene
of interest) (Average reference gene), where ribosomal 18s was used as
the reference gene.
Immunohistochemistry
For immunohistochemistry, murine and human aortas were cut into 5mm
paraffin sections. Antibodies for immunohistochemistry were as follows:
MMP-2 (R&D Systems, Inc, Minneapolis, Minn), MMP-9 (R&D Systems),
SM22a (ABCAM, Inc, Cambridge Mass), and SM a-actin (Sigma Cy3-la-
beled clone 1A4, Product number C6198). To assess for SMC apoptosis
and proliferation, caspase-3 (Cell Signaling, Danvers, Mass) and Ki-67
(Santa Cruz, SantaCruz,Calif) stainingwas performed. In brief, after antigen
retrieval (Vector Laboratories, Burlingame, Calif) with heat-induced epitope
retrieval, the primary antibodies were detected with the Vectastain Elite Kit
(Vector Laboratories). Visualization was done with DAB (DAKO North
America, Inc, Carpinteria,Calif). Formurine SMa-actin,DAPI (Vectashield
HardSet Mountin Medium with DAPI, catalog no. H-1500) counterstaining
was used (Vector Laboratories). For human SM a-actin, Permanent Red Ta-
bles and Substrate Buffer (DAKO) were used. Counterstaining was done
with Harris Hematoxylin 1 (Richard-Allen Scientific, Kalamazoo, Mich).
For caspase-3, Methyl Green (DAKO) counterstaining was used. Negative
controls were run with the omission of the primary antibody. Images were
acquired by using the 43, 103, and 253 objectives on a Zeiss microscope
(Zeiss, Peabody, Mass) equipped with an AxioCam digital camera (Zeiss)
with theAxioCamversion 4.6 software program in theUniversity ofVirginia
Cardiovascular Research Center.
For histochemistry, 5mm paraffin sections were assessed for histopathol-
ogy by using a modified Russell-Movat pentachrome method and hematox-
ylin and eosin (Laboratory Methods in Histotechnology, Armed Forces
Institute of Pathology). Movat- and hematoxylin and eosin–stained slides
were imaged as above at the Academic Computing Health Sciences Center
at the University of Virginia.
Human Tissue Harvest
The collection of human aortic aneurysm tissue was approved by the
University of Virginia institutional review board (no. 13178). Patients
undergoing open surgical operations for ascending or abdominal aortic
aneurysm repair or coronary artery bypass grafting (CABG)were consented.
The ascending or abdominal aortic aneurysmal wall (n ¼ 10 each) was
resected at the time of the operation and immediately snap-frozen and later
analyzed by means of qPCR and immunohistochemistry. Control tissue was
only obtained from the ascending aorta during CABG procedures (n ¼ 10)
from the proximal aortotomy. Patients who had evidence of atherosclerotic
ascending aorta, ascending aortic aneurysm, or any known history of
collagen vascular disease or aneurysm were excluded from collection as
control subjects.
Statistical Analysis
Comparisons were made between elastase- and saline (control)–perfused
animals. Similarly, human aneurysms and control aortas were compared.
Statistical analysis was performed with an unpaired, 2-tailed, Mann–Whitney
test by using GraphPad Prism 5 software (GraphPad Software, La Jolla, Calif).
Data are represented as the mean ( standard error of the mean) of the subject
group versus the mean ( standard error of the mean) of the control group.
Data were subjected to the Grubb’s test to detect any outliers (GraphPad
Software).ardiovascular Surgery c Volume 138, Number 6 1393




SFIGURE 1. A, Elastase perfusion of the infrarenal abdominal aorta. B, An explanted abdominal aortic aneurysm 14 days after elastase perfusion. C, Graph
demonstrating aortic aneurysm formation at 14 days after elastase (and not saline) perfusion. Importantly, at 7 days, no differences in aortic diameter are
evident between elastase- and saline-treated animals.RESULTS
Aortic Aneurysms Develop at 14 Days
The baseline aortic diameters in mice before and immedi-
ately after elastase perfusion were equivalent to the aortic di-
ameters in saline-perfused mice. At 7 days after surgical
intervention, the aortic diameter in elastase-perfused mice
remained similar to that seen in saline-perfused mice
(60.0%  9.13% vs 53.3%  18.3%, P ¼ .49; Figure 1,
C). However, by 14 days, the aortic diameter was signifi-
cantly larger after elastase perfusion (100%  9.6% vs
59.5%  18.9%, P ¼ .0002; Figure 1, C).
Decreased SM Gene Expression Occurs Before
Experimental Aneurysms
qPCR was used to determine the gene expression profiles
of aortas after elastase or saline perfusion. At 1 and 3 days1394 The Journal of Thoracic and Cardiovascular Suafter surgical intervention, no differences in expression of
the SM marker genes SM a-actin or SM22A were identified
(data not shown). At 7 days, however, phenotypic modula-
tion of SMCs was evident because elastase-perfused mice
had a 78% reduction in SM22a expression (3.22E-05 
9.18E-06 vs 1.49E-04  2.4E-05, P ¼ .003) compared
with that seen in saline-perfused animals, well before the
aneurysm phenotype was present (Figure 2). In addition,
SM a-actin expression was 85% less in aortas from elastase-
treated animals compared with that seen in saline-treated
animals (7.19E-05  1.88E-05 vs 4.65E-04  1.41E-04,
P ¼ .034, Figure 2). MMP-2 expression was increased by
80% in elastase-treated animals compared with that seen
in saline control–treated animals (1.24E-04  4.02E-05 vs
6.89E-051.06E-05, P ¼ .044, data not shown).
At 14 days, SM22a (3.19E-05 8.10E-06 vs 3.31E-04
8.85E-05, P ¼ .004) and SM a-actin (2.35E-04  4.69E-05rgery c December 2009




Svs 1.39E-03  6.67E-04, P ¼ .023) expression remained
90% and 83% less, respectively, in aneurysmal aortas com-
pared with that seen in saline-treated aortas (Figure 2). In
addition, MMP-2 expression was 240% higher 14 days after
elastase perfusion compared with that seen after saline
perfusion (1.56E-04  3.52E-05 vs 4.59E-05  1.77E-05,
P ¼ .026, data not shown).
Immunohistochemistry did not demonstrate discernable
differences in SM22a or SM a-actin expression at 1 or 3
days (data not shown). In addition, minimal differences in
the expression of these SM marker genes were evident at 7
days by means of histology. Evidence for some downregu-
lation of SM22a was seen in some sections but was not
marked (blue arrowheads, Figure 3). However, at 14 days,
immunohistochemistry did confirm markedly less SM22a
and SM a-actin in the media of experimental aneurysms
compared with that seen in saline-treated mice (Figure 4).
MMP-2 and MMP-9 levels were increased in the media
and adventitia at 7 and 14 days but not at 1 or 3 days in
elastase-treated aortas compared with those seen in saline-
treated aortas (Figures 3 and 4). Interestingly, careful
examination of immunohistochemistry demonstrated that,
consistent with repression of SMCmarkers being an integral
characteristic of aortic dilation and remodeling, some de-
crease in SMC marker gene expressions is evident in sa-
line-perfused animals compared with that seen in a normal
noninjured aorta. However, this reduction in SMC marker
gene expression was consistently and noticeably less than
that seen in elastase-perfused animals at 14 days. Impor-
tantly, apoptosis, as assessed by cleaved (active) caspase-3
staining at 7 days, was minimal in both elastase- and sa-
line-perfused aortas, suggesting that the observed decrease
in SMC marker gene expression was not due to active cell
loss (Figure 3). These images were analyzed with Image
Pro Plus 4.5 software for the percentage of the vessel wall
positive for caspase-3. Positive staining was not increased
in elastase-perfused mice (0.04%  0.01%) compared
with that seen in saline-perfused mice (0.5% 0.2%). Sim-
ilarly, there was little evidence of apoptosis at 14 days.
Decreased SM Gene Expression in Ascending and
Abdominal Aneurysms in Human Subjects
Human ascending aortic aneurysms harvested at the time
of open surgical resection had 98% less SM a-actin
expression compared with that seen in control ascending
aortic tissue obtained during CABG (aneurysm, 1.48E-06
 6.33E-07; control, 9.08E-05  5.86E-05; P ¼ .0026;
Figure 4). In addition, MMP-2 expression was increased
by more than 1600% in aneurysms compared with that
seen in control tissue (6.33E-04  3.17E-04 vs 3.60E-05
 9.83E-06, P ¼ .0003, Figure 5). As determined by means
of immunohistochemistry, SM22a and SM a-actin staining
were markedly decreased in the aortic wall from both
ascending and abdominal aneurysms compared with that
seen in control aortas (Figure 6). In addition, immunohisto-
chemistry demonstrated more medial and adventitial
MMP-2 and MMP-9 in human aneurysms compared with
that seen in control aortas (Figure 6). Evidence for apoptosis
FIGURE 2. Quantitative polymerase chain reaction analysis of smooth muscle marker genes at 7 and 14 days after elastase/saline perfusion. SM22a and SM
a-actin expression is downregulated in elastase-treated aortas at 7 and 14 days after perfusion. Standard error bars are shown.The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 6 1395




SFIGURE 3. Histochemistry and immunohistochemistry in mice 7 days after elastase or saline perfusion. Little differences in elastin are evident by means of
Movat staining, with intact elastin in both treatment groups. Some early degradation might be present in regions of the aorta (blue arrowheads) after elastase
perfusion compared with that seen after saline perfusion. Expression of matrix metalloproteinase (MMP) 2 and 9 appears to be upregulated at 7 days after
elastase compared with that seen after saline. Minimal activated (cleaved) caspase-3 staining is present in either group (brown positive stain, methyl green
nuclear counterstain). Images were obtained at 253 magnification, except for caspase-3, which was obtained at 103 magnification.obtained by means of Caspase-3 staining was present in an-
eurysmal aortas, with less evidence for apoptosis in control
aortic tissue. It is likely in these advanced aneurysms requir-
ing resection that cellular loss can explain at least some of
the decreased SMC marker gene expression.
DISCUSSION
The role of SMCs during the development and progres-
sion of aortic aneurysms is not well defined. In this study
we demonstrate a decrease in SM marker genes in advanced
human ascending and abdominal aneurysms compared with
control tissue from the ascending aorta. These findings
might be explained by SMC apoptosis. To test the hypothe-
sis that SMC phenotypic switching occurs early in aneurysm
formation, we used a murine model and demonstrated thatSMCs undergo phenotypic modulation early before aneu-
rysm formation, and this does not appear to be explained
by the loss of SMCs caused by apoptosis. To prove that
SMC phenotypic modulation occurs during progression of
aneurysmal disease in human subjects would require access
to small aneurysmal aortic tissue in which SMCs are still
prevalent or access to a specific marker for phenotypically
modulated SMCs, which is yet to be reported. In advanced
aneurysms, such as those treated with surgical repair,
many SMCs have undergone apoptosis.1
Vascular SMCs in adults are plastic and can undergo re-
versible changes in their phenotype in response to changing
environmental cues.2 In response to vascular injury, the
SMC increases its rate of cell proliferation and migration
and its ability to synthesize extracellular matrix, playingFIGURE 4. Histochemistry and immunohistochemistry in mice 14 days after elastase or saline perfusion. Movat staining demonstrated destruction of the
medial elastin layer in elastase-treated animals. SM a-actin and SM22a (arrowheads) are downregulated compared with that seen in saline controls. Expres-
sion of matrix metalloproteinase (MMP) 2 and 9 is markedly increased in elastase-treated animals. There is little activated (cleaved) caspase-3 staining in either
elastase- or saline-treated animals (brown staining positive, methyl green nuclear counterstain). Images were obtained at 253 magnification, except for
caspase-3, which was obtained at 103 magnification.
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Ailawadi et al Evolving Technology/Basic ScienceFIGURE 5. Quantitative polymerase chain reaction in human ascending aortic aneurysms and control ascending aortic tissue. SM a-actin expression is sig-
nificantly decreased in ascending aortic aneurysms, whereas matrix metalloproteinase (MMP) 2 expression is increased compared with that seen in control
aortas. Standard error bars are shown.a critical role in vascular repair.2 Teleologically, the ability
of SMCs to remain plastic likely conferred a survival advan-
tage for repair of injured vessels.2,3 However, the negative
effect of this plasticity is that it can predispose the SMC to
potentially detrimental phenotypic modulation in response
to abnormal environmental cues and can contribute to the
progression of vascular disease.2,3
This concept of phenotypic modulation has been well
studied in models of atherosclerosis and restenosis. Balloon
injury of the murine and rabbit carotid artery results in phe-
notypic switching of SMCs characterized by loss of SM
marker genes, including SM22A, SM a-actin, and SM
myosin heavy chain, concurrent with proliferation and
migration of SMCs to the lesion.7 These findings have
also been observed in human lesions at autopsy after balloon
angioplasty.8The Journal of Thoracic and CThe exact mechanisms involved in regulation of SM phe-
notype remain to be elucidated. In vitro and in vivo models
have shown that expression of these SM marker genes is de-
pendent on multiple CC(A/T)6CG elements and their bind-
ing factor, serum response factor.9-11 The serum response
factor and CC(A/T)6CG axis appears to be required for
SMC phenotypic modulation in vascular injury.3,12
Evidence from our laboratory also has shown that a G/C re-
pressor element within the SM22A promoter mediates
transcriptional repression of this gene in experimental ath-
erosclerosis.3,13 A number of transcriptional pathways, in-
cluding Kru¨ppel-like factor (KLF) 4, have been shown to
mediate repression of marker genes in vitro and in a ligation
model of vascular injury in vivo.14,15
Evidence from other work supports an important role for
SMCs in the pathophysiology of aortic aneurysms. LongoE
T
/B
SFIGURE 6. Immunohistochemistry in human ascending and abdominal aortic aneurysms (AA) and control ascending aortas. SM a-actin and SM22a are
downregulated in aortic aneurysms compared with that seen in control aortas. Expression of matrix metalloproteinase (MMP) 2 and 9 is increased in aneu-
rysmal tissue. Apoptosis (caspase-3) is evident in ascending and abdominal aortic aneurysms and, to a lesser extent, in control aortas. All images were obtained
at 103 magnification.ardiovascular Surgery c Volume 138, Number 6 1397




Sand colleagues16 suggested a critical role for SMCs in exper-
imental aneurysm formation. MMP-2 knockout mice are re-
sistant to experimental aortic aneurysms using a model of
abluminal calcium chloride application. Reconstitution of
these mice with wild-type bone marrow did not alter this re-
sistance, suggesting that MMP-2 derived from outside the
bone marrow is critical.17 It is well known that MMP-2 is
expressed in high levels by SMCs in vitro in response to
a number of inflammatory cytokines. There is also evidence
suggesting that mutations within SMC genes contribute to at
least some human familial aneurysm syndromes. For exam-
ple, missense mutations in ACTA2, an isoform of SM a-
actin, result in abnormal SMC contractile function and are
believed to cause approximately 14% of inherited ascending
thoracic aneurysms.18 Moreover, mutations in the SMC spe-
cific myosin heavy chain gene (MYH11) are associated with
ascending aortic aneurysms.19 Collectively, these findings
suggest that alterations in SMCs, including production of
MMPs and contractile function, likely contribute to the
development of aneurysms.
There has been recent excitement regarding the role of
transforming growth factor (TGF) b in the pathogenesis of
aortic aneurysms.17 However, the exact mechanisms by
which TGF-b signaling relates to abdominal aortic aneu-
rysm formation are unclear. Inhibition of TGF-b with anti-
body prevents aortic root aneurysms in the fibrillin-1
mutant (Marfan) mouse.20 Conversely, adenoviral overex-
pression of TGF-b results in stabilization of abdominal aor-
tic aneurysms in rats.21 At the leading edge of human
abdominal aortic aneurysms, apoptotic SMCs colocalize
with high levels of TGF-b, suggesting that TGF-bmight me-
diate apoptosis in aneurysms.22 During vascular develop-
ment, however, TGF-b is known to promote SMC
differentiation and production of SMC marker genes in
vivo and in vitro.23 In addition, mice deficient in TGF-b1
die in utero in large part because of the failure of mesenchy-
mal precursor cells to differentiate into vascular SMCs.24
Despite these paradoxic findings of the role of TGF-b, there
appears to be an important link between TGF-b signaling
and vascular SMCs during aneurysm formation.
There are several limitations to this study. First, our find-
ings of SMC phenotypic modulation before experimental
aneurysms are correlative and not causative. To prove a caus-
ative role would require the ability to prevent or alter SMC
phenotype before or after elastase perfusion.
Second, although we have experimental models that can
correlate with small aneurysms, the limited access to small
aneurysms (not requiring surgical treatment) in human sub-
jects limits our ability to assess whether phenotypic modula-
tion of SMCs occurs early in the course of human aortic
aneurysms.
The elastase perfusion model has certain shortcomings
that should be noted. The model does cause an initial dilation
after perfusion of 30% to 50% that is well described after1398 The Journal of Thoracic and Cardiovascular Seither elastase or saline perfusion.4-6 In addition, the elastase
model is admittedly rapid, with the development of an aneu-
rysm by 14 days. Nevertheless, this model has been exten-
sively studied and mimics human aneurysms with the
hallmark pathologic features, including matrix degradation,
increased cytokine production, and the presence of a chronic
inflammatory infiltrate.4-6 In addition, these SMC marker
genes are known to be expressed in a variety of other cell
types, including fibroblasts and myofibroblasts, in the set-
ting of wound repair.25 As such, we focused on the medial
wall of the aorta, where SMCs are the predominant cell
type. We infer that MMP-2 is being produced by SMCs,
among other cells, in the medial wall. MMP-2 is a constitu-
tive enzyme produced by multiple cell types. Because there
is no marker for phenotypically modulated SMCs, there is
no way to confirm that modulated SMCs are the source of
MMP-2 after elastase perfusion without lineage-tracing
studies.
We used an abdominal aortic aneurysm model, whereas
our analysis in human subjects was primarily of ascend-
ing aortic aneurysms (because of our ability to obtain
ascending aortic control tissue). Importantly, the embryo-
logic origin and risk factors for ascending and abdominal
aortic aneurysms are different. As such, the pathophysiol-
ogy of ascending and abdominal aneurysms might be dif-
ferent as well. We demonstrated a similar pattern of
decreased SMC marker genes and upregulation of
MMPs by means of immunohistochemistry in abdominal
aortic aneurysms. However, we do not have control tissue
from the abdominal aorta, making comparison somewhat
indirect.
Experimental murine and human aneurysms demonstrate
SMC phenotypic modulation characterized by reduced ex-
pression of SM marker genes and upregulation of MMPs.
These events in experimental models occur early before dis-
cernable differences in aneurysm formation. Because SMCs
can synthesize extracellular matrix proteins, they might be
an ideal target for therapy. The ability to alter SMC differen-
tiation has been marred by the fact that many of the regula-
tors of SMC maturation, including TGF-b1, TGF-b receptor
II, and SMAD5, result in embryonic lethality because of de-
fects in vascular maturation, SMC differentiation, or both.2,3
Future directions aimed at understanding and altering the
mechanisms that control phenotypic switching in aortic an-
eurysms will use the ability to conditionally knock out the
regulators of SMC phenotype. Targeting SMCs to a repara-
tive phenotype might provide a novel therapy in the treat-
ment of aortic aneurysms.
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Dr John S. Ikonomidis (Charleston, SC). I have no relation-
ships to disclose.
Gorav, this was a very interesting presentation. I have several
questions for you.
First, as you mentioned, it is well described that SMCs undergo
apoptosis during aneurysm development. How do you account for
the negative results seen with your animal model as opposed to the
results you saw in the human specimens?
Dr Ailawadi. For the reasons you note, I thought it was impor-
tant to show our caspase-3 data. We have also done Ki-67 staining
to assess proliferation. In our best assessment, the SMC count in
our model appears to be similar, suggesting that the SMCs are pres-
ent but are not expressing these marker genes. In our human sam-
ples, which are advanced lesions, there is loss of SMCs.
Dr Ikonomidis. In that regard, is it possible that the changes that
you are seeing could be explained by a regional heterogeneity phe-
nomenon? In this study you are comparing human ascending aortas
with murine abnormal aortas. Is it possible that there is a body of
evidence that suggests that regional heterogeneity exists within
the aorta, and could that contribute to these results?
Dr Ailawadi. It is certainly possible. We have investigated the
concept of regional heterogeneity in the past, and there do appear
to be differences along the aorta. We did analyze abdominal aortic
aneurysms, and they follow the same pattern, with downregulation
of SMmarker genes in these advanced human lesions that are being
resected as the human ascending aorta. However, we do not have
good control tissue for the abdominal aorta. Normal abdominal aor-
tas in human subjects are difficult to access, and that is why we
chose to use ascending aortas from human subjects as our correlate.
We believe that many of the effector pathways involved in ascend-
ing and abdominal aortas are quite similar.
Dr Ikonomidis. Next, MMP-2 can be produced by multiple cell
types. MMP-9 has been shown in this particular model to be
associated with or produced by the inflammatory infiltrate. You
have shown data that suggest that there is a phenotypic modulation,
and you have also shown data that there is upregulation in MMP-2
and MMP-9 expression. Do you have data that specifically
colocalizes production of MMP-2 and MMP-9 to a unique cell
with a specific phenotype?
Dr Ailawadi. That is the real challenge when we are trying to
correlate modulated SMCs. The way we analyze or identify
SMCs is by their marker genes, and because they lose those marker
genes, it becomes very difficult to assess that this is truly an SMC.
To answer your excellent question requires the use of unique
transgenic mice. These studies are currently underway in our labo-
ratorywith genetically alteredmicewith SMCs that are altered to ex-
press Lac Z, even if they lose their ability to express SM22. Our
preliminary studies demonstrate that SMCs still express MMP-2.
Dr Ikonomidis. The last question I have is that you are making
assertions about a phenotypic change in this study based on changes
in stains for an SMC actin and SM22. Do you have any data on any
more direct surrogates of phenotypic change, for example, KLF-4?
Dr Ailawadi. We are doing several ongoing studies along these
lines. KLF-4 is involved in the pathways of SMC modulation.
Dr Ikonomidis. Again, congratulations on this stimulating
work.ardiovascular Surgery c Volume 138, Number 6 1399
